Page 20 - பாதுகாப்பு ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses The DTRA Chem Bio Technologies, Vaccines and Therapeutics Division forms industry partnership with Evrys Bio to accelerate treatment for alphavirus, arenavirus and filovirus infections July 13, 2021 00:04 ET | Source: Evrys Bio Evrys Bio Doylestown, Pennsylvania, UNITED STATES DOYLESTOWN, Pa., July 13, 2021 (GLOBE NEWSWIRE) Evrys Bio, a biotech company developing Next Gen Antivirals, was awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents. The proposed drug intends to improve disease survival after exposure to one or more viruses from three families: alphaviruses, arenaviruses and filoviruses. Evrys Bio’s broad-spectrum antiviral technology is based on the discovery that certain human proteins, called sir

United statesEvrys bioLillian chiangTherapeutics divisionDefense programOther transaction authorityDepartment of defensePrinceton universityInternational partnersThreat networksDefense threat reduction agency chem bio technologiesUnited states department of defense doDefense threat reduction agencyNext gen antiviralsThreat reduction agencyChem bio technologies